Perspective Therapeutics, Inc.

CATX · NYSE · SIC 2834: Pharmaceutical Preparations
464
SEC Filings

Business Summary

Perspective Therapeutics, Inc. (CATX) is a clinical-stage biopharmaceutical company focused on targeted alpha therapy (TAT) for cancer treatment. Its pipeline includes VMT-α-NET and VMT01 product candidates, which have received Fast Track designation from the FDA. The company also develops PSV359, a novel asset under an IND application. Perspective operates manufacturing subsidiaries Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc., and is building a regional network of drug product finishing facilities.

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCATXdiscussed_in_filing Healthcare & Bio
topic_mentionCATXdiscussed_in_filing Healthcare & Bio
topic_mentionCATXdiscussed_in_filing Healthcare & Bio
topic_mentionCATXdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310000728387-26-000004EDGAR92K words
2025-03-262024-12-310000950170-25-045242EDGAR—
2024-03-282023-12-310001437749-24-009696EDGAR—
2022-09-282022-06-300001437749-22-023188EDGAR—
2021-09-272021-06-300001437749-21-022693EDGAR—
2020-09-252020-06-300001437749-20-020189EDGAR—
2019-09-272019-06-300001437749-19-019176EDGAR—
2018-09-262018-06-300001437749-18-017492EDGAR—
2017-09-282017-06-300001144204-17-050344EDGAR—
2016-09-092016-06-300001144204-16-123313EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-274328EDGAR25K words
2025-08-132025-06-300000950170-25-107619EDGAR—
2025-05-122025-03-310000950170-25-069314EDGAR—
2024-11-122024-09-300000950170-24-125399EDGAR—
2024-08-132024-06-300000950170-24-096148EDGAR—
2024-05-152024-03-310000950170-24-060427EDGAR—
2023-11-142023-09-300001437749-23-032036EDGAR—
2023-08-112023-06-300001437749-23-023340EDGAR—
2023-05-152023-03-310001437749-23-014658EDGAR—
2022-11-142022-09-300001437749-22-027304EDGAR—
2022-05-132022-03-310001437749-22-012202EDGAR—
2022-02-092021-12-310001437749-22-002803EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001193125-26-137930EDGAR1K words
2026-03-160000728387-26-000003EDGAR—
2026-02-030001193125-26-035508EDGAR—
2026-02-020001193125-26-032706EDGAR—
2026-01-140001193125-26-012259EDGAR—
2026-01-120001193125-26-009846EDGAR—
2026-01-090001193125-26-008277EDGAR—
2025-12-010001193125-25-303895EDGAR—
2025-11-100001193125-25-274318EDGAR—
2025-11-060001193125-25-268124EDGAR—

464 total filings indexed. 432 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology targeted-alpha-therapy clinical-stage-biopharmaceuticals radiopharmaceuticals

Company Identity

CIK0000728387
TickerCATX
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 539612eed2b6e5457de6bea5e3d526d4ced91c181bc91dc8eb76a9c91ebe88ed
parent: 198c1492bde00c9bc8e6d46959d9332937bd2c07b956e0ea5385814df7743dd0
content hash: f3e69492140c360dcb488670f04c8edb65ac1679969ae158abf70440b5fe1353
signed: 2026-04-13T04:44:12.435Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf